newsfilter
← Latest News
Business Wire·

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

–Mr. Cumbo brings deep experience commercializing new medicines for people with rare genetic diseases– –Company announces retirement of Director Edward Kaye, M.D., from the Board– Stoke Therapeutics, Inc.